Growth Metrics

GeneDx Holdings (WGS) Net Cash Flow (2020 - 2026)

GeneDx Holdings has reported Net Cash Flow over the past 7 years, most recently at -$11.1 million for Q1 2026.

  • Quarterly Net Cash Flow fell 176.41% to -$11.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$5.8 million through Mar 2026, down 136.04% year-over-year, with the annual reading at $19.8 million for FY2025, 236.78% up from the prior year.
  • Net Cash Flow was -$11.1 million for Q1 2026 at GeneDx Holdings, down from $9.0 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $76.6 million in Q1 2023 and troughed at -$93.3 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$16.0 million (2024), against an average of -$18.0 million.
  • Year-over-year, Net Cash Flow tumbled 239.85% in 2023 and then skyrocketed 1101.76% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$67.4 million in 2022, then surged by 118.36% to $12.4 million in 2023, then skyrocketed by 120.67% to $27.3 million in 2024, then plummeted by 66.94% to $9.0 million in 2025, then tumbled by 222.61% to -$11.1 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Net Cash Flow are -$11.1 million (Q1 2026), $9.0 million (Q4 2025), and $21.8 million (Q3 2025).